Pharmacotherapeutic Approaches Research Articles

How to Distinguish Non-Inflammatory from Inflammatory Pain in RA?

Managing non-inflammatory pain in rheumatoid arthritis (RA) can be a huge burden for the rheumatologist. Pain that persists despite optimal RA treatment is extremely challenging for patient and physician alike. Here, we outline the latest research relevant to distinguishing non-inflammatory from inflammatory RA pain and review the current understanding of its neurobiology and management. Nociplastic pain is a recently introduced term by the international pain community. Its definition encompasses the non-inflammatory pain of RA and describes pain that is not driven by inflamed joints or compromised nerves, but that is instead driven by a functional reorganisation of the central nervous system (CNS). Insights from all areas of nociplastic pain research, including fibromyalgia, support a personalised pain management approach for non-inflammatory pain of RA, with evidence-based guidelines favouring use of non-pharmacological interventions. Future developments include novel CNS targeting pharmacotherapeutic approaches to treat nociplastic pain.

Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach

Liver cancer, particularly hepatocellular carcinoma (HCC), represents a significant global health burden with limited treatment options and poor prognosis. This article provides a comprehensive overview of pharmacotherapy for liver cancer, focusing on both established and emerging drugs. Current standard-of-care treatments, including sorafenib and lenvatinib, target key pathways involved in tumor growth and angiogenesis. However, their efficacy is often limited, prompting ongoing research into novel therapeutic approaches. Emerging immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have shown promise in clinical trials, offering new avenues for personalized treatment strategies. Additionally, targeted therapies aimed at specific genetic alterations, such as FGFR inhibitors for FGFR-altered HCC, demonstrate potential for improved outcomes in select patient populations. These abstract highlights the evolving landscape of pharmacotherapy for liver cancer and underscores the need for further research to optimize treatment efficacy and patient outcomes. Keywords Multi­kinase Inhibitors, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC), Sorafenib

Concept of Dementia and its Management in Unani System of Medicine: A Review

Dementia, derived from Latin meaning “without mind,” is a significant global health concern and the seventh leading cause of death, characterized by the progressive deterioration of cognitive functions, including memory, thinking, and behaviour. As the global population ages, dementia's prevalence is anticipated to rise dramatically, with an estimated 50 million cases currently worldwide, projected to reach 152 million by 2050. The two primary causes are Alzheimer's disease and vascular disorders. In the Unani system of medicine, dementia, referred to as Nisyān, is attributed to the dysfunction of three internal faculties: imagination (Qüwwate Khayal), thought (Qüwwate Fikr), and memory (Qirwwate Zikr), influenced by factors such as abnormal temperament (Sü' Mizāj) and disruptions in structural integrity. Clinical features vary, with early signs including short-term memory loss and disorientation. The condition can be classified into primary (degenerative) and secondary (acquired) dementias. Risk factors include age, family history, and lifestyle choices. Treatment principles in Unani medicine focus on addressing the underlying causes, correcting brain temperament, evacuating morbid matter, and employing dietary, regimental, and pharmacotherapeutic approaches. This holistic framework underscores the importance of traditional medical systems in understanding and managing dementia, advocating for a comprehensive approach to treatment that encompasses both modern and traditional practices. Keywords: unani system of medicine, Dementia, cognitive decline, Dietotherapy, su’Mizaj

Triple agonists of GIP, GLP-1, and glucagon - the future of obesity treatment: a review of the latest findings

Background: The epidemic of obesity and type 2 diabetes poses a growing challenge to global public health, necessitating effective intervention strategies. Currently conducted research on novel pharmacotherapeutic approaches to obesity treatment is yielding promising results. Among them are the triple agonists of GIP/GLP/GCG (glucose-dependent insulinotropic peptide/ glucagon-like peptide/ glucagon) receptors, representing the latest discovery. Preclinical studies and phase I and II trials demonstrate significant clinical prospects for GIP/GLP/GCG receptor agonists. Aim of the study: This paper aims to summarize and analyze the current knowledge on triple agonists of GIP/GLP-1/GCG and their impact on body weight based on clinical studies conducted in recent years and currently ongoing. Material and methods: The search was conducted using the PubMed, Google Scholar, and NIH databases. Articles published between 1971 and 2022 were analyzed. The keywords used were "triple agonists," "obesity," "GIP," "GLP-1," and "glucagon." Results: According to our best knowledge, there are currently clinical trials underway for four GIP/GLP-1/ glucose-dependent insulinotropic peptideagon triagonists, including NN9423NC9204-1706, efpegtrutide, SAR441255, and retatrutide. Studies on retatrutide have shown promising results, with observed weight reduction of up to 17 kg. Additionally, another triagonist, efocipegtrutyd, besides its effects on weight loss, demonstrates the ability to prevent liver fibrosis and has neuroprotective effects. Conclusion: The action of GIP/GLP-1/GCG triple agonists is multifaceted, and preliminary research results are encouraging further exploration of their potential. Despite promising outcomes, continued research is necessary to gain a deeper understanding of their mechanism of action and to assess their long-term effects. Such studies will be crucial in providing information to support the development of personalized therapeutic strategies and optimizing their clinical utility in diverse patient populations.

Empowering probiotics with high xanthine transport for effective hyperuricemia management

ABSTRACT Hyperuricemia, a prevalent metabolic disorder, poses a susceptibility to various complications. The conventional pharmacotherapeutic approaches for hyperuricemia often entail notable adverse effects, posing substantial clinical challenges. Hence, the imperative lies in the development of novel, safe and effective strategies for preventing and treating hyperuricemia. Here, we developed a probiotic Escherichia coli Nissle 1917 strain, designated as YES301, which contains a rationally designed xanthine importer XanQ, enabling efficient uptake of xanthine and hypoxanthine, consequently leading to reduced serum uric acid concentrations and amelioration of renal impairments in a murine model of hyperuricemia. Importantly, YES301 exhibited a therapeutic efficacy comparable to allopurinol, a conventional uric acid-lowering agent, and manifesting fewer adverse effects and enhanced biosafety. These findings highlight the promising potential of engineered probiotics in the management of hyperuricemia through reducing intestinal purine levels.

Pharmacological Treatments for Gambling Disorder: A Current Review of Literature

This narrative review aims to examine pharmacological treatment modalities for gambling disorder (GD) by analyzing recent literature and identifying significant trends in the field. A thorough examination of relevant literature, focusing primarily on recent studies and reviews, in order to identify significant pharmacological treatment approaches and current trends. Results: The review identifies several pharmacological approaches for GD, including opioid antagonists, serotonergic agents, dopaminergic modulators, glutamatergic agents, and mood stabilizers. Recent studies suggest that opioid antagonists such as naltrexone and nalmefene show promise in reducing gambling urges and behaviors. Additionally, serotonergic agents like selective serotonin reuptake inhibitors (SSRIs) have demonstrated efficacy in alleviating the impulsivity and compulsivity associated with GD. Dopaminergic and glutamatergic agents, while showing some potential, require further investigation for their role in GD treatment. Mood stabilizers, particularly lithium, appear to be beneficial, especially in individuals with co-occurring bipolar affective disorder. Pharmacological interventions play a crucial role in the management of GD, with opioid antagonists and SSRIs emerging as promising options. However, further research is needed to elucidate the optimal pharmacotherapeutic approach and develop more targeted treatments for GD. Integration of pharmacotherapy with psychotherapeutic interventions may enhance treatment outcomes for individuals with GD.

Mitochondrial protein deacetylation by SIRT3 in osteoclasts promotes bone resorption with aging in female mice

ObjectivesThe mitochondrial deacetylase sirtuin-3 (SIRT3) is necessary for the increased bone resorption and enhanced function of mitochondria in osteoclasts that occur with advancing age; how SIRT3 drives bone resorption remains elusive. MethodsTo determine the role of SIRT3 in osteoclast mitochondria, we used mice with conditional loss of Sirt3 in osteoclast lineage and mice with germline deletion of either Sirt3 or its known target Pink1. ResultsSIRT3 stimulates mitochondrial quality in osteoclasts in a PINK1-independent manner, promoting mitochondrial activity and osteoclast maturation and function, thereby contributing to bone loss in female but not male mice. Quantitative analyses of global proteomes and acetylomes revealed that deletion of Sirt3 dramatically increased acetylation of osteoclast mitochondrial proteins, particularly ATPase inhibitory factor 1 (ATPIF1), an essential protein for mitophagy. Inhibition of mitophagy via mdivi-1 recapitulated the effect of deletion of Sirt3 or Atpif1 in osteoclast formation and mitochondrial function. ConclusionsDecreasing mitophagic flux in osteoclasts may be a promising pharmacotherapeutic approach to treat osteoporosis in older adults.

Zingiber officinale Roscoe extract improves nigrostriatal dopaminergic activity in rotenone-induced Parkinsonian mice: Implication of COX-2/TNF-α/IL-6 and antioxidant enzyme crosstalk in the immunoinflammatory responses

Ethnopharmacological relevanceParkinson's disease (PD) is a chronic neurodegenerative disease that occurs progressively with time. Current PD treatments are symptomatic with moderate effects on striatal dopamine release. Previously, the ethnomedicinal benefits of Zingiber officinale Roscoe have been demonstrated to possess a broad range of pharmacological benefits, but no single data on its effect against nigrostriatal degeneration in PD model has been reported. AimProactive neuroprotective and pharmacotherapeutic approaches with asymptomatic effects are needed to prevent the progression of Parkinson's disease (PD) and maintain the appropriate population of dopaminergic neurons. Current treatments are symptomatic and can only elevate the striatal dopamine levels. Hence, the objective of the study is to elucidate the neuroprotective and neurorestorative properties of Zingiber officinale methanol extract (MEZO) on nigrostriatal degeneration implicated by immunoinflammatory responses in rotenone-challenged PD mice model. MethodsMale Swiss mice were injected with rotenone (2.5 mg/kg) intraperitoneally to induce PD symptoms 30 minutes prior to MEZO (50 and 100 mg/kg) and LD-CD (10 mg/kg) oral treatment for 28 days. Motor/neuromuscular behavior, dopamine, acetylcholinesterase (AChE), tyrosine hydroxylase (TH), α-synuclein (α-syn), cyclooxygenase-2 (COX-2), oxidative stress markers, inflammatory cytokines, and histopathology were evaluated. ResultsOur data showed that MEZO treatment attenuated sensorimotor and neuromuscular incompetence by up-regulating the expression of TH protein and dopamine release and maintaining AChE enzyme in the symptomatic mice. We observed that MEZO treatment prevented the formation of Lewis bodies (LBs) by inhibiting the aggregation of nigrostriatal α-Syn proteins, decreasing the release of pro-oxidant and pro-inflammatory mediators and cyclooxygenase-2 (COX-2) protein expression, increasing glutathione enzymes, and moderately abated the loss dopaminergic neurons in a dose-dependent effect in the symptomatic mice. ConclusionThese findings demonstrated that MEZO exhibited the potential neuroprotective and neurorestorative effect in the treatment and management of PD.

Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors.

G protein-coupled receptors (GPCRs) regulate every aspect of kidney function by mediating the effects of various endogenous and exogenous substances. A key concept in GPCR function is biased signalling, whereby certain ligands may selectively activate specific pathways within the receptor's signalling repertoire. For example, different agonists may induce biased signalling by stabilizing distinct active receptor conformations - a concept that is supported by advances in structural biology. However, the processes underlying functional selectivity in receptor signalling are extremely complex, involving differences in subcellular compartmentalization and signalling dynamics. Importantly, the molecular mechanisms of spatiotemporal bias, particularly its connection to ligand binding kinetics, have been detailed for GPCRs critical to kidney function, such as the AT1 angiotensin receptor (AT1R), V2 vasopressin receptor (V2R) and the parathyroid hormone 1 receptor (PTH1R). This expanding insight into the multifaceted nature of biased signalling paves the way for innovative strategies for targeting GPCR functions; the development of novel biased agonists may represent advanced pharmacotherapeutic approaches to the treatment of kidney diseases and related systemic conditions, such as hypertension, diabetes and heart failure.

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development.

With around one billion of the world's population affected, the era of the metabolic-associated fatty liver disease (MAFLD) pandemic has entered the global stage. MAFLD is a chronic progressive liver disease with accompanying metabolic disorders such as type 2 diabetes mellitus and obesity which can progress asymptomatically to liver cirrhosis and subsequently to hepatocellular carcinoma (HCC), and for which to date there are almost no approved pharmacologic options. Because MAFLD has a very complex etiology and it also affects extrahepatic organs, a multidisciplinary approach is required when it comes to finding an effective and safe active substance for MAFLD treatment. The optimal drug for MAFLD should diminish steatosis, fibrosis and inflammation in the liver, and the winner for MAFLD drug authorisation seems to be the one that significantly improves liver histology. Saroglitazar (Lipaglyn®) was approved for metabolic-dysfunction-associated steatohepatitis (MASH) in India in 2020; however, the drug is still being investigated in other countries. Although the pharmaceutical industry is still lagging behind in developing an approved pharmacologic therapy for MAFLD, research has recently intensified and many molecules which are in the final stages of clinical trials are expected to be approved in the coming few years. Already this year, the first drug (Rezdiffra™) in the United States was approved via accelerated procedure for treatment of MAFLD, i.e., of MASH in adults. This review underscores the most recent information related to the development of drugs for MAFLD treatment, focusing on the molecules that have come furthest towards approval.

A Pharmacotherapeutic Approaches for Managing Labour Pain Using Synthetic Drugs and Natural Therapies.

The birth of a child is a critical and potentially traumatic experience for women, entailing multiple physiological and psychosocial changes. The psychological effects of childbirth pain can have both immediate and long-term effects on the mother's health and her bond with her child. Many studies investigated the different ranges of synthetic drugs available for pain control in labour, inclusive of neuraxial analgesics, inhaled analgesics, and various opioids. The inadequate efficacy and unfavourable side effects of these synthetic drugs prevent appropriate pharmacotherapy, resulting in a quest for natural therapies for reducing labour pain. Herbal therapies (aromatherapy) using several essential oils obtained from various natural plants are another alternative that calms and manages the mind and body through aromatic compounds that have neurological and physiological effects. The review discussed the safety profile of various synthetic drugs with their dosage information and also deliberated on the mechanism and safety profile of various natural plants that are used in aromatherapy. The review also briefly highlighted the other non-pharmacological miscellaneous techniques such as TENS, hypnosis, immersion in water, acupuncture, massage, and different other tactics that aim to assist women in coping with pain in labour.

The Surgical Management of the Mesentery in Crohn's Disease

AbstractIncreasing evidence suggests that Crohn's disease is a primary mesenteropathy and that resection of the mesentery, or its exclusion from an anastomosis, may alter disease progression. If borne out in clinical trials, this observation would be welcome, as current pharmacotherapeutic approaches to Crohn's disease appear to have limited effect on disease progression. This article explores arguments for and against the alteration of mesenteric inputs by surgical means, in Crohn's disease.

Advancements In Pharmacotherapy for Hyperlipidemia: A Comprehensive Review of Recent Drug Innovations and Clinical Outcomes

Hyperlipidemia, characterized by elevated blood lipid levels, significantly contributes to cardiovascular diseases (CVDs), the leading cause of global mortality per the World Health Organization (WHO). Studies reveal a 20-30% increase in coronary heart disease risk for every 1 mmol/L rise in LDL-C levels. While statins are widely used, novel pharmacotherapeutic approaches are necessary for effective hyperlipidemia management and CVD risk reduction. Recent clinical trials demonstrate the efficacy of innovative drugs like proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering LDL-C levels and reducing adverse cardiovascular events. These findings highlight the potential of new therapies to enhance existing treatments for hyperlipidemia. Additionally, safety evaluations of emerging lipid-lowering agents address concerns about adverse effects and long-term risks. Despite progress, challenges persist in refining treatment strategies and ensuring equitable access to advanced therapies, especially for marginalized populations. Incorporating innovative pharmacotherapies into current approaches offers personalized and efficient hyperlipidemia management. Continued research and interdisciplinary collaborations are vital for advancing our understanding of lipid metabolism and translating scientific discoveries into improved patient outcomes and cardiovascular health. Ongoing innovation and investment in tailored hyperlipidemia therapies are crucial for better outcomes in individuals at risk of CVDs.
 Keywords: hyperlipidemia, pcsk9 inhibitors, bempedoic acid, evinacumab, inclisiran mipomersen, volanesorsen

557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis.

OBJECTIVES/GOALS: Renal fibrosis is a critical pathophysiological event in chronic kidney diseases. Our goal is to determine the ability of dual-inhibitor of transforming growth factor beta receptor 1 (TGFα²R1) and mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), TK850, on reducing kidney fibrosis. METHODS/STUDY POPULATION: To test the renal anti-fibrotic action ofdual TK850,8-10-week-old male and female C57BL/6mice with unilateral ureteral obstruction (UUO) induced kidney fibrosis were used. Mice were separated into 3 groups: group 1 contained mice that had UUO surgery (UUO control), group 2 contained mice prophylactically treated with TK850 thatstarted 7 days prior to UUO(UUO-P,20 mpk/d/ip), and group 3 contained mice interventionally treated with TK850 that started3 days after UUO(UUO-I,20 mpk/d/ip). Ten days following UUO the kidneys and blood were collected for analysis. Renal fibrosis was assessed from hydroxyproline content (measure of collagen)and histological collagen analysis using Picrosirius red stain. RESULTS/ANTICIPATED RESULTS: Renal hydroxyproline was increased equally in the UUO kidney of male (5.4 ± 0.41 µg/10mg, n=5) and female mice (5.5 ± 0.50 µg/10mg, n=5) compared to the contralateral control kidney (2.9 ± 0.14 µg/10mg, n=10). TK850 treatment in UUO-P mice (n=10, 3.4 ± 0.24 µg/10mg) and UUO-I mice (4.30 ± 0.20 µg/10mg, n=10) had significantly reduced hydroxyproline levels. Histopathological evaluation revealed that kidney injury increased collagen deposition in the UUO kidney (17.1 ± 0.43% collagen positive area, n=10) compared to the control kidney (2.0 ± 0.23%, n=10). TK850 treatment in UUO-P mice significantly attenuated collagen deposition (10.5 ± 0.38%, n=10), while UUO-I had significantly reduced collagen deposition as well (13.1 ± 0.25%, n=10). DISCUSSION/SIGNIFICANCE: Taken together, these results validate the dual TGFβR1/MAP4K4 inhibitor, TK850 as a potential therapeutic to mitigate renal fibrosis and supports the emergence of a combinational pharmacotherapeutic approach for multi-factorial kidney diseases.

Treatment of Late Infective Prosthetic Endocarditis Complicated by Cerebral Infarction with Vegetations: Pharmacotherapeutic Approach (Case Report)

Prosthetic endocarditis is a serious complication in a long term. Vegetation as a thromboembolic complication leads to neurologic deficit varying in severity.
 Case description. A 35-year-old female patient F. underwent surgical treatment at the Department of Surgical Treatment of Acquired Heart Diseases of the National Amosov Institute of Cardiovascular Surgery on September 07, 2016: aortic valve replacement with wrapping tape operation II. The patient was discharged from the hospital on the 9th day after surgery in a satisfactory condition. On November 20, 2019, the patient was admitted to the Institute with the diagnosis of late infective prosthetic aortic valve endocarditis, status post aortic valve replacement and wrapping tape operation in 2016, first-degree atrioventricular block, cerebral infarctions in multiple locations with hemorrhagic transformation, with aphasia elements, ataxia, right-sided pyramidal insufficiency and suspected meningitis. After 21 days of drug therapy, the patient responded to treatment successfully and was discharged from the hospital in a satisfactory condition without surgical treatment.
 Conclusions. Taking into consideration the serious condition of the patient, timely and carefully selected drug therapy can be the correct solution for the treatment of patients with late infective endocarditis. Thus, surgery is not always the treatment of choice.

Current Pharmaco-therapeutic Approach on COVID-19 Admitted Patients in a Corona-dedicated Hospital in Khulna

Background: The COVID-19 pandemic has been demanding possible pharmaco-therapeutic options to reduce the mortality associated with the disease by trying out the clinical efficacy of various therapeutic agents. Objective: Our purpose of the study was to explore the current pharmaco-therapeutic approaches to COVID-19 patients in different clinical categories. Methods: This is a descriptive observational study where 300 clinically diagnosed COVID-19-positive patients were included following inclusion & exclusion criteria at the study center. Patients’ demographic profiles and treatment plans were obtained using a specially designed form. The data were collated and analyzed using a Microsoft Excel spreadsheet and results were expressed in percentages. Results: Remdesivir, moxifloxacin, dexamethasone, meropenem, enoxaparin and other supportive drugs with different percentages in mild, moderate, severe & critical cases were frequently prescribed. Besides non-invasive oxygen therapy has been given in almost all patients. Conclusion: Antiviral, LMWH, broad-spectrum antibiotics, corticosteroids and other symptomatic drugs are the major treatment options for different clinical categories of COVID-19 patients. Mediscope 2024;11(1): 13-21

The effectiveness of the original anticonvulsant Galodif® — a GABAA receptor modulator for alcohol withdrawal syndrome

BACKGROUND: The development of new drugs to improve the effectiveness of treatment and rehabilitation programs for patients suffering from addiction diseases, which are non-addictive and have a stimulating effect on detoxification processes in the body, can increase the effectiveness of therapy and reduce the cost of treatment. A deficiency of GABAergic inhibition in brain structures plays a leading role in the occurrence of paroxysmalness. The innovative anticonvulsant Galodif® (1-[(3-chlorophenyl)(phenyl)methyl]urea), a GABAA receptor modulator, has low toxicity and hepatoprotective properties, which allows it to be recommended for use in the treatment of patients with alcohol dependence.
 AIM: The aim of this study is to evaluation of the effectiveness of the use of the anticonvulsant drug galodif1 in complex therapy in patients with alcohol dependence with compulsive and paroxysmal disorders with pathological craving for alcohol when withdrawing of alcohol.
 MATERIALS AND METHODS: A limited open-type clinical study of the therapeutic effectiveness of the innovative anticonvulsant galodif1 included 128 male patients (average age 38.3 ± 8.9 years) with a diagnosis of “Mental and behavioral disorders as a result of alcohol consumption, dependence syndrome” (F10.232) and “Mental and behavioral disorders as a result of alcohol consumption, withdrawal states” (F10.302). 68 patients received Galodif® 300 mg per day as an anticonvulsant for 21 days. 60 patients made up the comparison group, receiving carbamazepine at a dose of 400 mg per day.
 RESULTS: The use of the anticonvulsant Galodif® in complex therapy of patients revealed: normothymoleptic activity of the drug; when assessing depression on the Hamilton Depression Rating Scale (HDRS), the average total score decreased from 28.3 ± 1.3 to 5.7 ± 1.9, and a reduction in unmotivated fear and anxiety was noted; vegetative stabilizing effect with a sympathicolytic component with normalization of heart rate; reduction of headaches; weakening or disappearance of pathological desire during withdrawal syndrome in 88% of cases, in the post-withdrawal state — in 57% of cases; taking the drug did not cause any unwanted side effects.
 CONCLUSIONS: The use of the anticonvulsant Galodif®, which modulates GABAA receptors, has low toxicity and detoxification properties and does not cause side effects, has been proposed as one of the modern pharmacotherapeutic approaches in the treatment of patients with alcohol dependence.

Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders

Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.

The pharmacology and pharmacotherapeutic approach of various neurological disorders

The pharmacology and pharmacotherapeutic approach of various neurological disorders

МОДЕЛЬ РАЗВИТИЯ БИСФОСФОНАТ-АССОЦИИРОВАННОГО ОСТЕОМИЕЛИТА НИЖНЕЙ ЧЕЛЮСТИ В ЭКСПЕРИМЕНТЕ С ЛАБОРАТОРНЫМИ КРЫСАМИ

Purulent-inflammatory diseases of the maxillary system remain one of the urgent problems in the work of dentists and maxillofacial surgeons due to the high frequency, increased severity and prevalence of the process, a tendency to relapse, and increased antibiotic resistance due to a long period of uncontrolled use of the latter by the population. The choice of the bisphosphonate-associated osteomyelitis model is due, on the one hand, to the widespread use of this group in a number of malignant neoplasms, osteoporosis, and, on the other, to the frequent development of osteonecrosis of the jaw as a complication of bisphosphonate therapy, which can occur after any surgical dental procedure. The undoubted advantage of this model is the relative simplicity of its execution technique, which does not require an expensive material and technical base, the use of highly pathogenic and highly contagious microorganisms, keeping animals in a bacteriological laboratory, and the safety of conducting experiments. Experimental modeling of bisphosphonate-associated osteomyelitis may reveal new aspects in the etiopathogenesis of diseases of the maxillofacial region and justify the correction of nondrug and pharmacotherapeutic approaches to the prevention and treatment of complications.